Curi RMB Capital LLC Sells 530,315 Shares of Kenvue Inc. (NYSE:KVUE)

Curi RMB Capital LLC lowered its holdings in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 48.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 558,482 shares of the company's stock after selling 530,315 shares during the period. Curi RMB Capital LLC's holdings in Kenvue were worth $12,918,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. SAM Advisors LLC grew its stake in shares of Kenvue by 2.5% in the third quarter. SAM Advisors LLC now owns 52,459 shares of the company's stock worth $1,213,000 after acquiring an additional 1,274 shares during the last quarter. Huntington National Bank boosted its stake in Kenvue by 26.5% in the 3rd quarter. Huntington National Bank now owns 4,161 shares of the company's stock worth $96,000 after purchasing an additional 871 shares in the last quarter. KBC Group NV grew its position in Kenvue by 114.0% during the 3rd quarter. KBC Group NV now owns 966,160 shares of the company's stock valued at $22,348,000 after purchasing an additional 514,580 shares during the last quarter. ICICI Prudential Asset Management Co Ltd increased its stake in Kenvue by 4.0% during the 3rd quarter. ICICI Prudential Asset Management Co Ltd now owns 423,060 shares of the company's stock valued at $9,785,000 after purchasing an additional 16,460 shares in the last quarter. Finally, Saturna Capital Corp raised its holdings in Kenvue by 29.9% in the third quarter. Saturna Capital Corp now owns 1,334,860 shares of the company's stock worth $30,875,000 after buying an additional 307,039 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.

Kenvue Stock Performance

Shares of Kenvue stock traded up $0.47 on Thursday, hitting $23.61. 14,014,768 shares of the company's stock were exchanged, compared to its average volume of 18,062,609. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The stock has a market capitalization of $45.27 billion, a PE ratio of 42.62, a PEG ratio of 2.15 and a beta of 1.36. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $23.95. The company has a 50-day simple moving average of $22.73 and a 200-day simple moving average of $20.63.

Kenvue (NYSE:KVUE - Get Free Report) last released its earnings results on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.01. The company had revenue of $3.90 billion for the quarter, compared to the consensus estimate of $3.92 billion. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. Kenvue's quarterly revenue was down .4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.31 earnings per share. As a group, equities analysts anticipate that Kenvue Inc. will post 1.07 EPS for the current year.

Kenvue Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, November 27th. Investors of record on Wednesday, November 13th will be issued a $0.205 dividend. This represents a $0.82 annualized dividend and a yield of 3.47%. The ex-dividend date of this dividend is Wednesday, November 13th. Kenvue's dividend payout ratio is 149.09%.

Wall Street Analysts Forecast Growth

KVUE has been the subject of several analyst reports. Deutsche Bank Aktiengesellschaft raised their price target on shares of Kenvue from $23.00 to $24.00 and gave the company a "buy" rating in a research report on Wednesday, August 7th. Piper Sandler upped their price target on Kenvue from $20.00 to $21.00 and gave the company a "neutral" rating in a report on Monday, September 23rd. JPMorgan Chase & Co. lifted their price objective on Kenvue from $24.00 to $25.00 and gave the stock an "overweight" rating in a report on Friday, October 11th. Jefferies Financial Group started coverage on shares of Kenvue in a report on Tuesday, September 24th. They set a "buy" rating and a $27.00 price target on the stock. Finally, Royal Bank of Canada cut shares of Kenvue from an "outperform" rating to a "sector perform" rating and set a $24.00 price objective for the company. in a report on Tuesday, September 24th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, Kenvue currently has an average rating of "Hold" and an average target price of $22.64.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.